ÂÜÀòÂÒÂ×

David Millan serves as the Chief Scientific Officer at Auron Therapeutics since December 2021, where efforts focus on transforming malignant cells through differentiation therapy to address cancer. Additionally, Millan is a Scientific Advisory Board Member at Vesper Bio ApS and an AACR Chemistry in Cancer Research Steering Committee Member. With extensive prior experience, Millan was the Vice President and Head of Chemistry at Foghorn Therapeutics, leading innovative projects in drug development, and held senior roles at FORMA Therapeutics and Pfizer, driving medicinal chemistry strategies and contributing to several clinical candidates. Millan began a career in medicinal chemistry with foundational roles at Vertex Pharmaceuticals and as a Postdoctoral Research Fellow at the University of Nottingham, after earning a PhD in Synthetic Organic Chemistry and a Bachelor's degree with honors from Flinders University.